Latest Conference

Despite a 2018 American Academy of Pediatrics clinical update that recommends use of postexposure prophylaxis for prevention of the tick-borne disease in children younger than 8 years, Wesley Kufel, PharmD, BCPS, BCIDP, FCCP, FIDSA, points out many clinicians are unaware of this. He also discusses its efficacy at preventing the disease in this patient population.

Results from a new survey taken this past summer show immunization confidence waning among the public and some factual uncertainty around immunization. In this time of disinformation and misinformation, Ruth Lynfield, MD, discusses an approach clinicians can take in counseling parents who may have concerns about the vaccine as well as other strategies to increase immunization adherence.

In his new position, Gareth Morgan, MS, MBA, provides insights on antibiotic development strategies he would like to see during his tenure.

Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study.

At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study.

Ashlan Kunz Coyne, PharmD, MPH, discusses the potential of combining antibiotics with phage mixture therapy in treating these types of infections.

Jesse Clark, MD, MSc, discusses a study’s subset preliminary findings looking at this form of PrEP in this patient population.

Dumkow discusses her goals for her tenure as well as professional societies' roles in public health advocacy and AI.

At IDWeek, the company reported promising phase 1/2 trial results for its shingles vaccine candidate Z-1018, demonstrating strong immune responses and favorable tolerability.

Lori Handy, MD, MSCE, emphasized that rebuilding public trust requires continuous engagement and a collective rethinking of medical communication.

Phase 3 results for tebipenem HBr suggest an oral carbapenem could provide an effective alternative to IV therapy for multidrug-resistant UTIs.

A systematic review presented at IDWeek 2025 found that pneumococcal serotypes unique to Merck’s 21-valent conjugate vaccine, Capvaxive, are more prevalent among US adults and show higher rates of antibiotic resistance compared to those unique to PCV20.

At IDWeek 2025, Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Researchers say affordable lenacapavir could transform global HIV prevention efforts amid rising infection rates.

Invivyd’s Chief Scientific Officer Robert Allen, PhD, provides insights on the company's investigational monoclonal antibody, VYD2311, as well as its REVOLUTION clinical program.

Findings from the ongoing ROAR registry show that fecal microbiota, live-jslm (RBL), maintains strong efficacy and safety in preventing recurrent Clostridioides difficile infection (rCDI) in routine US clinical practice.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

IDWeek Chair, Infectious Diseases Society of America, Yohei Doi, MD, provides some insights on the happenings at this year’s event.

Combined or individual use of maternal RSVpreF and infant nirsevimab achieved high antibody levels without safety concerns, supporting current RSV prevention strategies.

A nationwide analysis found that more than 1,500 additional HIV specialists are needed—particularly in the south—to meet national HIV care targets, underscoring major geographic and socioeconomic disparities in provider access.

New 96-week results from the study show that Dovato is as effective as Biktarvy in maintaining viral suppression in adults with HIV, while leading to less weight gain and fewer drug-related adverse events.

Jacinda Abdul-Mutakabbir, PharmD, MPH, provides insights on her recently published study on this topic and how the 2 are connected.

Jose Alexander, MD, offers insights on these antimicrobial combinations when treating against this bacterium.

Emily Olsen, PhD, offers some insights on this underdiagnosed infection, including describing antimicrobial studies, particularly in biofilm and intracellular environments. Her findings look to create a standardized approach for treating all forms of the different presentations of bartonellosis.

Athena Hobbs, PharmD, BCIDP, looked at this issue through the lens of treating urinary tract infections.

In part 2 of the conversation, David Relman, MD, discusses the importance of the research and medical communities in shaping future work in this area as well as the potential severe consequences of Mirror Life in a worse case scenario.

David Relman, MD, discusses the theoretical issues of "mirror life," how the scientific community could potentially research natural chirality synthetic life, and how mirror molecules may be a way to extract beneficial research from the concept.

From predicting viral outbreaks via fungal spores and combating drug-resistant gonorrhea to advancing fungal detection through genomic sequencing and improving antiviral resistance testing for vulnerable patients, and more.